Former Dendreon CEO Gold's New Cell Therapy Business Partners With Kite
This article was originally published in Scrip
Executive Summary
With insights into what's needed to make a cell therapy for cancer succeed, former Dendreon Corp. CEO Mitchell Gold is shepherding new technology for closely-watched immunotherapies into the clinic through his latest company Alpine Immune Sciences Inc., which has entered into a $535m-plus partnership with Kite Pharma Inc.
You may also be interested in...
Immune-Focused Discovery Firm Alpine Goes Public With Nivalis Merger
Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.